GLP-1 Medications and Heart Health: What the Clinical Trials Actually Show

Medically reviewed by a licensed healthcare professional. Last updated March 2026.

Key Takeaways

• The SELECT trial showed semaglutide reduced major cardiovascular events by 20% in people with obesity and existing heart disease, even without diabetes.
• The FDA approved Wegovy for cardiovascular risk reduction in March 2024, making it the first obesity medication with a heart-health indication.
• The SOUL trial found oral semaglutide reduced cardiovascular events by 14% in people with type 2 diabetes.
• The SURPASS-CVOT trial confirmed tirzepatide is at least as effective as dulaglutide for cardiovascular protection in type 2 diabetes, with a stronger expanded MACE reduction.
• The American College of Cardiology's 2025 guidance now recommends GLP-1 receptor agonists as a preferred treatment for obesity in patients with cardiovascular risk.
• Heart disease remains the leading killer in states like Mississippi, Alabama, and Louisiana, where access to these treatments could make the biggest difference.

For years, the conversation around GLP-1 medications focused almost entirely on weight loss and blood sugar. That changed in a big way when the SELECT trial results dropped in late 2023. Suddenly, cardiologists were paying attention to the same drugs endocrinologists had been prescribing for years.

The question shifted from "do these help with weight?" to "can these actually prevent heart attacks and strokes?" The clinical data now gives us a clear answer. And it's worth understanding what these trials found, because the implications go well beyond the scale.

If you're still sorting out the differences between the major GLP-1 medications, our complete guide to GLP-1 weight loss medications covers the basics.

The SELECT Trial: Semaglutide's Cardiovascular Breakthrough

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was the first large-scale study to test whether a GLP-1 medication could reduce heart events in people who had obesity and cardiovascular disease but did not have diabetes ^[1].

Study Design

The trial enrolled 17,604 adults aged 45 and older across 41 countries. All participants had a BMI of 27 or higher and established cardiovascular disease, but no diabetes. They were randomly assigned to receive either weekly semaglutide 2.4 mg (the Wegovy dose) or placebo, on top of their standard heart medications. Mean follow-up was about 40 months.

Results That Changed the Field

The headline number: a 20% reduction in major adverse cardiovascular events (MACE), defined as the combination of cardiovascular death, nonfatal heart attack, and nonfatal stroke. The hazard ratio was 0.80, with a confidence interval of 0.72 to 0.90 and a p-value below 0.001 ^[1].

Participants on semaglutide were one-fifth less likely to experience a heart attack, stroke, or cardiovascular death compared to placebo. And these benefits appeared on top of statins and blood pressure drugs patients were already taking.

A subsequent analysis also showed significant reductions in heart failure-related hospitalizations ^[2].

What About Side Effects?

The trade-off was higher discontinuation in the semaglutide group (16.6% vs. 8.2%), mostly due to GI issues like nausea. That's consistent with what we know about GLP-1 side effects generally. For a deeper comparison of how these medications stack up, check out our Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound comparison.

The SOUL Trial: Oral Semaglutide Joins the Conversation

The SOUL trial asked a slightly different question: can oral semaglutide (Rybelsus) reduce cardiovascular events in people with type 2 diabetes and high cardiovascular risk ^[3]?

What It Found

The trial enrolled 9,650 patients aged 50 and older with type 2 diabetes and either established cardiovascular disease, chronic kidney disease, or both. Over a mean follow-up of nearly four years, oral semaglutide 14 mg reduced MACE by 14% compared to placebo (hazard ratio 0.86, p = 0.006).

The biggest driver? A 26% reduction in nonfatal heart attacks. Nonfatal strokes dropped 12%, and cardiovascular deaths fell 7% ^[3].

This led the FDA to approve oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes in October 2025, making it the first oral GLP-1 with that indication ^[4].

SURPASS-CVOT: Tirzepatide's Cardiovascular Profile

Tirzepatide (the active ingredient in Mounjaro and Zepbound) works on both GLP-1 and GIP receptors, which is part of why it tends to produce greater weight loss. But the cardiovascular question remained open until the SURPASS-CVOT results were published in 2025 ^[5].

Trial Design and Results

This trial compared tirzepatide head-to-head against dulaglutide (Trulicity), an older GLP-1, in adults with type 2 diabetes and established cardiovascular disease. Over a median follow-up of four years:

The primary endpoint (3-point MACE) met noninferiority but not superiority. However, the expanded 4-point MACE that included coronary revascularization procedures was significantly reduced with tirzepatide ^[5]. All-cause mortality also numerically favored tirzepatide.

Still Waiting on SURMOUNT-MMO

The really big tirzepatide cardiovascular trial, SURMOUNT-MMO, is still enrolling. It's testing tirzepatide in people with obesity (without diabetes) and cardiovascular disease or risk factors. With about 15,000 participants across 27 countries, results are expected around 2027 ^[6]. This trial could do for tirzepatide what SELECT did for semaglutide.

What the FDA and ACC Now Recommend

These trial results have already changed how guidelines approach GLP-1 medications and heart health.

FDA Cardiovascular Indications

• March 2024: Wegovy (semaglutide 2.4 mg injection) approved for cardiovascular risk reduction in adults with established CVD and overweight or obesity ^[7].
• October 2025: Rybelsus (oral semaglutide) approved for cardiovascular risk reduction in adults with type 2 diabetes at high cardiovascular risk ^[4].

ACC 2025 Clinical Guidance

The American College of Cardiology released expert consensus guidance in 2025 that positions semaglutide and tirzepatide as the preferred medications for weight management when cardiovascular optimization is a goal. The guidance specifically states that patients should not be required to "try and fail" lifestyle changes before starting medication, though lifestyle interventions should always be offered alongside pharmacotherapy ^[8].

This is a meaningful shift. For years, obesity medications were treated as a last resort. Now major cardiology organizations are saying: if your patient has obesity and cardiovascular risk, consider GLP-1 therapy early.

Why This Matters Most in the Heart Disease Belt

Heart disease is the leading cause of death in the United States, but the burden is not evenly distributed. Southern and Appalachian states carry a dramatically higher toll.

According to CDC data, the states with the highest heart disease death rates include ^[9]:

• Mississippi: 248 per 100,000 (vs. national average of 162)
• Alabama: 234 per 100,000
• Louisiana: 224 per 100,000
• West Virginia: 209.5 per 100,000

These are the same regions where obesity rates tend to be highest and access to newer treatments most limited. If you're in one of these states, we maintain provider directories for cities across these areas, including Biloxi, Mississippi, Mobile, Alabama, and Baton Rouge, Louisiana.

Expanding access to GLP-1 treatments in these high-risk areas could be one of the most impactful public health interventions available right now.

The Bottom Line

The cardiovascular evidence for GLP-1 medications is no longer preliminary. Three major trials have each demonstrated meaningful reductions in heart attacks, strokes, and related events. The FDA has acted on this data, and major cardiology organizations have updated their guidelines accordingly.

This doesn't mean GLP-1 medications are for everyone. Cost, side effects, and individual medical history all matter. But for people carrying extra weight alongside cardiovascular risk, the conversation with their doctor should now include whether a GLP-1 medication belongs in the plan.

Frequently Asked Questions

Can GLP-1 medications actually prevent heart attacks?

Yes, based on current trial data. The SELECT trial showed semaglutide reduced the combined risk of heart attack, stroke, and cardiovascular death by 20% in people with obesity and existing heart disease. The benefit was seen on top of standard treatments like statins and blood pressure medications.

Do I need to have diabetes for GLP-1 heart benefits?

Not necessarily. The SELECT trial specifically enrolled people without diabetes, showing cardiovascular benefits from semaglutide based on obesity and existing heart disease alone. However, the SOUL trial also showed benefits in people with type 2 diabetes.

Is tirzepatide (Mounjaro/Zepbound) as good for the heart as semaglutide?

The SURPASS-CVOT trial showed tirzepatide is at least as effective as another GLP-1 (dulaglutide) for cardiovascular protection in type 2 diabetes. However, we're still waiting on the SURMOUNT-MMO trial, which will test tirzepatide's heart benefits specifically in people with obesity. Results are expected around 2027.

Has the FDA approved any GLP-1 for heart health?

Yes. In March 2024, the FDA approved Wegovy (semaglutide injection) for reducing cardiovascular risk in adults with established heart disease and overweight or obesity. In October 2025, oral semaglutide (Rybelsus) received a similar approval for adults with type 2 diabetes at high cardiovascular risk.

How long do you need to take GLP-1 medications to see heart benefits?

In the SELECT trial, cardiovascular benefits began to emerge within the first year and continued to build over the roughly 3.5-year study period. However, these are typically long-term medications, and stopping them may reduce or reverse the benefits over time.

Are the heart benefits from the weight loss or the medication itself?

This is still being studied. While weight loss itself improves cardiovascular risk factors, analyses from SELECT suggest the cardiovascular benefits of semaglutide go beyond what weight loss alone would explain. GLP-1 medications appear to have direct anti-inflammatory and vascular effects that contribute to heart protection.

Sources

1. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial) - NEJM
2. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure - The Lancet
3. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL Trial) - NEJM
4. FDA Approves Oral Semaglutide for Cardiovascular Risk Reduction - Novo Nordisk
5. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT) - NEJM
6. SURMOUNT-MMO Trial Design - Obesity (Wiley)
7. Wegovy Receives FDA Approval for Cardiovascular Risk Reduction - Novo Nordisk
8. 2025 ACC Expert Consensus on Medical Weight Management for Cardiovascular Health - JACC
9. Heart Disease Mortality by State - CDC